Publications
2022
- Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Cancers (Basel). 2022 Jul 23;14(15):3589. doi: 10.3390/cancers14153589. PMID: 35892848.
- SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC Jr, Lu Z, Guo L, Chen Y, Zhou J. Mol Oncol. 2022 Jul;16(13):2558-2574. doi: 10.1002/1878-0261.13208. Epub 2022 Mar 25. PMID: 35278271.
- State of the science: Contemporary front-line treatment of advanced ovarian cancer. Hinchcliff E, Westin SN, Herzog TJ. Gynecol Oncol. 2022 Jul;166(1):18-24. doi: 10.1016/j.ygyno.2022.04.021. Epub 2022 May 17. PMID: 35589433.
- Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC Jr, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Cancers (Basel). 2022 Jun 23;14(13):3077. doi: 10.3390/cancers14133077. PMID: 35804849.
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003. PMID: 35658487.
- The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. Gynecol Oncol. 2022 Jun;165(3):560-567. doi: 10.1016/j.ygyno.2021.11.019. Epub 2022 Mar 30. PMID: 35606067.
- SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr. J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471. PMID: 35642638.
- Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan V. Cancers (Basel). 2022 May 19;14(10):2498. doi: 10.3390/cancers14102498. PMID: 35626102.
- Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Silva EG, Lawson BC, Ramalingam P, Liu J, Shehabeldin A, Marques-Piubelli ML, Malpica A. Hum Pathol. 2022 Apr 12:S0046-8177(22)00087-9. doi: 10.1016/j.humpath.2022.04.008. PMID: 35427637.
- Should secondary cytoreduction be used in recurrent ovarian cancer? Westin SN. Clin Adv Hematol Oncol. 2022 Apr;20(4):215-217. PMID: 35389385.
- Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Gynecol Oncol. 2022 Apr;165(1):82-89. doi: 10.1016/j.ygyno.2022.02.006. Epub 2022 Feb 23. PMID: 35216808.
- Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. J Cancer Res Clin Oncol. 2022 Apr;148(4):803-821. doi: 10.1007/s00432-021-03885-z. Epub 2022 Jan 30. PMID: 35094142.
- Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. iScience. 2022 Feb 14;25(3):103923. doi: 10.1016/j.isci.2022.103923. eCollection 2022 Mar 18. PMID: 35252817.
- Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK. Cancers (Basel). 2022 Mar 15;14(6):1496. doi: 10.3390/cancers14061496. PMID: 35326647.
- Endothelial p130cas confers resistance to anti-angiogenesis therapy. Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Cell Rep. 2022 Jan 25;38(4):110301. doi: 10.1016/j.celrep.2022.110301. PMID: 35081345.
- Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. Sasano T, Gonzalez-Delgado R, Muñoz NM, Carlos-Alcade W, Cho MS, Sheth RA, Sood AK, Afshar-Kharghan V. J Thromb Haemost. 2022 Jan;20(1):104-114. doi: 10.1111/jth.15544. Epub 2021 Oct 15. PMID: 34608736
Older
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.